Evidence map›Paper›PMID 30400527›Full record

ReviewMicromachines2017

Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals.

Noel S Ha, Saman Sadeghi, R Michael van Dam

Open access · goldAbstract readReview
In one paragraph

Review in Micromachines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Development and Optimization ofACS pharmacology & translational science · 2023
    Review
  6. Development of a Lensless Radiomicroscope for Cellular-Resolution Radionuclide Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Quality Assessment of Tc-99m Methylene Diphosphonate (MDP) Radiopharmaceutical Prepared Using Different Cold Kit Fractionation Methods.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
  14. High-throughput radio-TLC analysis.Nuclear medicine and biology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Noel S HaDepartment of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA 90095, USA. noelha@ucla.edu.ORCID 0000-0002-3275-577X
Saman SadeghiCrump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA. samsadeghi@mednet.ucla.edu.
R Michael van DamDepartment of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA 90095, USA. mvandam@mednet.ucla.edu.ORCID 0000-0003-2316-0173
University of California, Los Angeles · US

Funding

Automated microfluidic production of high specific activity PET tracers to enable routine CNS imagingR21AG049918 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2015 to 2017
$693k
High-throughput radiochemistry platform for accelerated discovery and development of novel PET imaging agents for cancerR21CA212718 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2017 to 2018
$616k
NCI NIH HHS R21 CA212718NIA NIH HHS R21 AG049918
6 · The paper itself

Abstract

Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET) or single photon emission tomography (SPECT) scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers) must undergo quality control (QC) testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i) pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii) radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a discussion of efforts to directly miniaturize the test or examples in the literature that could be implemented for miniaturized QC testing.

Indexed as

lab-on-a-chipmicrofluidicspharmaceuticalspositron emission tomography (PET)quality control (QC) testingradiopharmaceuticalssensorsingle photon emission computed tomography (SPECT)

Identifiers

PMID30400527
PMCPMC6190332
OpenAlexW2768353133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.